An open label, Phase II dose escalation and expansion study to evaluate the safety and efficacy of propagermanium (PPG) added to stable angiotensin receptor blocker therapy (irbesartan) for the treatment of patients with proteinuria

Trial Profile

An open label, Phase II dose escalation and expansion study to evaluate the safety and efficacy of propagermanium (PPG) added to stable angiotensin receptor blocker therapy (irbesartan) for the treatment of patients with proteinuria

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2018

At a glance

  • Drugs Irbesartan/propagermanium (Primary) ; Propagermanium (Primary) ; Irbesartan
  • Indications Proteinuria; Renal failure
  • Focus Adverse reactions
  • Acronyms DMX-200
  • Sponsors Dimerix Bioscience
  • Most Recent Events

    • 01 Feb 2018 Planned number of patients changed from 60 to 30.
    • 14 Sep 2015 According to a Sun Biomedical media release, analysis of interim data from the first 15 patients in this study will be used to support the application for an Orphan Drug indication in patients with chronic kidney disease.
    • 14 Sep 2015 According to a Sun Biomedical media release, the first patient has been enrolled in this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top